NASDAQ:ATRA 12 January 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%.

9 March 2026

NASDAQ:ATRA·NASDAQ:QURE·NASDAQ:RGNX·Pharmaceutical Industry·Stock Market

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a rare post-transplant cancer. The stock was volatile, swinging between $4.77 and $15.40 as investors reacted to the news, with volume exceeding 1.4 million shares.

12 January 2026

NASDAQ:ATRA·Pharmaceutical Industry·Stock Market